Literature DB >> 33270228

G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers.

Nadia Arang1, J Silvio Gutkind1.   

Abstract

G protein-coupled receptors (GPCRs) and heterotrimeric G proteins play central roles in a diverse array of cellular processes. As such, dysregulation of GPCRs and their coupled heterotrimeric G proteins can dramatically alter the signalling landscape and functional state of a cell. Consistent with their fundamental physiological functions, GPCRs and their effector heterotrimeric G proteins are implicated in some of the most prevalent human diseases, including a complex disease such as cancer that causes significant morbidity and mortality worldwide. GPCR/G protein-mediated signalling impacts oncogenesis at multiple levels by regulating tumour angiogenesis, immune evasion, metastasis, and drug resistance. Here, we summarize the growing body of research on GPCRs and their effector heterotrimeric G proteins as drivers of cancer initiation and progression, and as emerging antitumoural therapeutic targets.
© 2020 Federation of European Biochemical Societies.

Entities:  

Keywords:  G protein-coupled receptors; GTPases; angiogenesis; cancer; cancer metabolism; immune therapy; inflammation; metastasis; precision medicine; signal transduction

Mesh:

Substances:

Year:  2020        PMID: 33270228      PMCID: PMC8849590          DOI: 10.1002/1873-3468.14017

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  303 in total

1.  The deficiency of Gαq leads to enhanced T-cell survival.

Authors:  Dashan Wang; Yugao Zhang; Yan He; Yan Li; Frances E Lund; Guixiu Shi
Journal:  Immunol Cell Biol       Date:  2014-06-24       Impact factor: 5.126

2.  Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.

Authors:  Matthew D Shirley; Hao Tang; Carol J Gallione; Joseph D Baugher; Laurence P Frelin; Bernard Cohen; Paula E North; Douglas A Marchuk; Anne M Comi; Jonathan Pevsner
Journal:  N Engl J Med       Date:  2013-05-08       Impact factor: 91.245

3.  Smoothened variants explain the majority of drug resistance in basal cell carcinoma.

Authors:  Scott X Atwood; Kavita Y Sarin; Ramon J Whitson; Jiang R Li; Geurim Kim; Melika Rezaee; Mina S Ally; Jinah Kim; Catherine Yao; Anne Lynn S Chang; Anthony E Oro; Jean Y Tang
Journal:  Cancer Cell       Date:  2015-03-09       Impact factor: 31.743

4.  Activation of rat frizzled-1 promotes Wnt signaling and differentiation of mouse F9 teratocarcinoma cells via pathways that require Galpha(q) and Galpha(o) function.

Authors:  T Liu; X Liu; H y Wang; R T Moon; C C Malbon
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

5.  Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.

Authors:  T Hida; Y Yatabe; H Achiwa; H Muramatsu; K Kozaki; S Nakamura; M Ogawa; T Mitsudomi; T Sugiura; T Takahashi
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

6.  Signaling from G protein-coupled receptors to ERK5/Big MAPK 1 involves Galpha q and Galpha 12/13 families of heterotrimeric G proteins. Evidence for the existence of a novel Ras AND Rho-independent pathway.

Authors:  S Fukuhara; M J Marinissen; M Chiariello; J S Gutkind
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

Review 7.  Targeting cancer-derived adenosine: new therapeutic approaches.

Authors:  Arabella Young; Deepak Mittal; John Stagg; Mark J Smyth
Journal:  Cancer Discov       Date:  2014-07-17       Impact factor: 39.397

8.  Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.

Authors:  Fa-Xing Yu; Jing Luo; Jung-Soon Mo; Guangbo Liu; Young Chul Kim; Zhipeng Meng; Ling Zhao; Gholam Peyman; Hong Ouyang; Wei Jiang; Jiagang Zhao; Xu Chen; Liangfang Zhang; Cun-Yu Wang; Boris C Bastian; Kang Zhang; Kun-Liang Guan
Journal:  Cancer Cell       Date:  2014-05-29       Impact factor: 31.743

9.  RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation.

Authors:  Jianqi Yang; Lance T Platt; Biswanath Maity; Katelin E Ahlers; Zili Luo; Zhibo Lin; Bandana Chakravarti; Stella-Rita Ibeawuchi; Ryan W Askeland; Jolanta Bondaruk; Bogdan A Czerniak; Rory A Fisher
Journal:  Oncotarget       Date:  2016-10-25

10.  Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms.

Authors:  G Nishikawa; S Sekine; R Ogawa; A Matsubara; T Mori; H Taniguchi; R Kushima; N Hiraoka; K Tsuta; H Tsuda; Y Kanai
Journal:  Br J Cancer       Date:  2013-02-12       Impact factor: 7.640

View more
  19 in total

1.  Oncogene addiction to GNAS in GNASR201 mutant tumors.

Authors:  Aditya More; Ichiaki Ito; Valsala Haridas; Saikat Chowdhury; Yue Gu; Princess Dickson; Natalie Fowlkes; John Paul Shen
Journal:  Oncogene       Date:  2022-07-25       Impact factor: 8.756

Review 2.  cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach.

Authors:  Muhammad Bilal Ahmed; Abdullah A A Alghamdi; Salman Ul Islam; Joon-Seok Lee; Young-Sup Lee
Journal:  Cells       Date:  2022-06-24       Impact factor: 7.666

3.  Tumor-derived ARHGAP35 mutations enhance the Gα13-Rho signaling axis in human endometrial cancer.

Authors:  Hiroshi Yagi; Ichiro Onoyama; Kazuo Asanoma; Minoru Kawakami; Shoji Maenohara; Keisuke Kodama; Yumiko Matsumura; Norio Hamada; Emiko Hori; Kazuhisa Hachisuga; Masafumi Yasunaga; Tatsuhiro Ohgami; Kaoru Okugawa; Hideaki Yahata; Kiyoko Kato
Journal:  Cancer Gene Ther       Date:  2022-10-18       Impact factor: 5.854

Review 4.  The emerging roles of Gα12/13 proteins on the hallmarks of cancer in solid tumors.

Authors:  Suhail Ahmed Kabeer Rasheed; Lalitha Vaishnavi Subramanyan; Wei Kiang Lim; Udhaya Kumari Udayappan; Mei Wang; Patrick J Casey
Journal:  Oncogene       Date:  2021-10-23       Impact factor: 9.867

5.  SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.

Authors:  Haiying Fu; Huarong Zhou; Yanyan Qiu; Jianfei Wang; Zhiming Ma; Hongping Li; Feng Zhang; Chenxi Qiu; Jianzhen Shen; Tingbo Liu
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

Review 6.  Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.

Authors:  Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

Review 7.  The Role of Serotonin in Breast Cancer Stem Cells.

Authors:  William D Gwynne; Mirza S Shakeel; Adele Girgis-Gabardo; John A Hassell
Journal:  Molecules       Date:  2021-05-26       Impact factor: 4.411

Review 8.  Latest update on chemokine receptors as therapeutic targets.

Authors:  Wing Yee Lai; Anja Mueller
Journal:  Biochem Soc Trans       Date:  2021-06-30       Impact factor: 5.407

Review 9.  Strategies towards Targeting Gαi/s Proteins: Scanning of Protein-Protein Interaction Sites To Overcome Inaccessibility.

Authors:  Britta Nubbemeyer; Anna Pepanian; Ajay Abisheck Paul George; Diana Imhof
Journal:  ChemMedChem       Date:  2021-03-22       Impact factor: 3.466

10.  Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen.

Authors:  Jenna Giubilaro; Doris A Schuetz; Tomasz M Stepniewski; Yoon Namkung; Etienne Khoury; Mónica Lara-Márquez; Shirley Campbell; Alexandre Beautrait; Sylvain Armando; Olivier Radresa; Jean Duchaine; Nathalie Lamarche-Vane; Audrey Claing; Jana Selent; Michel Bouvier; Anne Marinier; Stéphane A Laporte
Journal:  Nat Commun       Date:  2021-08-03       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.